IRRAS Announces Changed Publication Date for the Q4 2022 Interim Report
Stockholm, Sweden, February 1, 2023 – IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced that the publication of the interim report for the period from October to December 2022 (“Q4 2022 Interim Report”) will be published on Thursday, 16 February 2023.
|Report||Previously Announced Date||New Date|
|Q4 2023 interim report||22 February 2023||16 February 2023|
Financial calendar for 2023
|Annual report 2022||27 April 2023|
|Q1 2023 interim report||17 May 2023|
|Annual General Meeting||7 June 2023|
|Q2 2023 interim report||24 August 2023|
|Q3 2023 interim report||9 November 2023|
|Q4 2023 interim report||21 February 2024|
IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).
For more information, please contact:
Director, Investor Relations
+46 102 11 5172
The information was released for public disclosure, through the agency of the contact person above, on February 1, 2023, at 8:30 (CET).